Figure 6.

Strategies and tools to detect asymptomatic transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) earlier in the disease course. Patient and clinician engagement/education, tissue screening, biomarkers and gene biobanks, and analyses of clinical data derived from the electronic health records, longitudinal registries, and clinical trials can be used to calibrate the optimal use of diagnostic tools (ie, targeted questionnaires, electrocardiogram, echocardiography, cardiac magnetic resonance imaging, cardiac scintigraphy, cardiac biomarkers). Over time, learning algorithms using machine learning and artificial intelligence may allow for the iterative improvement of accurate diagnosis and enable patient identification and appropriate screening of patients at risk for ATTR-CM. EHR: electronic health record